Company Overview
SOPHiA GENETICS SA functions as a cloud-native software technology company dedicated to the healthcare sector, specifically providing the SOPHiA DDM platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities within the Health Information Services industry. This positioning within the healthcare sector allows the firm to leverage advanced software capabilities to process complex biological and clinical data, addressing critical needs in genomic medicine and precision diagnostics. The company currently employs 415 individuals and maintains a total market capitalization of $338.28M, with annual revenue recorded at $77.27M over the trailing twelve months. These valuation and revenue figures indicate that while the company has achieved significant scale in revenue generation, its market capitalization reflects the market's current assessment of its growth potential and profitability status in a capital-intensive software development environment.
Financial Health
The company reported a trailing twelve-month revenue of $77.27M, yet it recorded a net income of $-78,999,000 and an EBITDA of $-69,168,000, revealing a substantial structural gap where operating expenses significantly outpace top-line earnings. This divergence between revenue and net income highlights a cost structure dominated by high fixed costs, likely related to R&D and cloud infrastructure, which are common in early-stage software scaling but currently suppress bottom-line profitability. Free cash flow stands at $-16,462,000, indicating that the company is burning cash to fuel its expansion, which limits immediate financial flexibility but is a typical characteristic of growth-oriented technology firms reinvesting heavily in product development. Margins reflect this financial profile, with a gross margin of 67.4% suggesting efficient core product delivery, contrasted sharply by an operating margin of -85.4% and a profit margin of -102.2% that underscore heavy overhead burdens relative to sales. Liquidity management is supported by $70.29M in cash against $63.02M in debt, resulting in a debt-to-equity ratio of 133.67% which suggests a leveraged balance sheet typical for capital-light software businesses seeking to maximize tax shields and leverage growth. Short-term liquidity appears robust given a current ratio of 1.96, implying the company holds sufficient current assets to cover its short-term liabilities without immediate distress. Finally, return on equity is -110.0% and return on assets is -27.9%, metrics that reveal management is currently prioritizing expansion over returning value to shareholders, resulting in negative returns on the capital base deployed.
Valuation Assessment
Valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of earnings, while the forward P/E is calculated at -8.43, implying that the market prices the stock based on anticipated future profitability rather than current performance. The price-to-book ratio is 6.86, indicating that the market assigns a significant premium to the company's intangible assets, such as its software platform and intellectual property, relative to its tangible book value. Alternative valuation measures show a price-to-sales ratio of 4.38 and an EV/EBITDA of -4.79, suggesting investors are valuing the firm primarily on its revenue trajectory and potential for future profitability rather than current cash generation or earnings multiples. Price momentum is defined by a 52-week high of $5.70 and a 52-week low of $2.58, meaning the stock is trading within a range that captures significant volatility over the past year. The stock's beta is 1.14, which indicates that the share price is 14% more volatile than the broader market, exposing investors to higher price swings during periods of market instability or sector-specific shifts.
Growth & Income
Revenue growth year-over-year is 22.4%, demonstrating a strong top-line expansion, whereas earnings growth is N/A due to the company's current net losses, implying that profitability lags behind revenue generation as the business scales. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, indicating a strategy of reinvesting all available capital back into the business to fund research and development. This reinvestment approach is consistent with the negative free cash flow and negative EBITDA, where the firm forgoes income distribution to preserve growth opportunities in the competitive health information services landscape. Overall, the growth and income profile is characterized by rapid revenue expansion coupled with significant cash burn and no current income generation, typical of a high-growth biotech software company seeking to establish a dominant market position before achieving sustained profitability.